Cinctive Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Cinctive Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78M	Buy	+8,300	New	+$2.63M	0.1%	242

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Cinctive Capital Management's PRAX Position: Q2 2026 in Review

Cinctive Capital Management opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 8,300 shares worth $2.78M. The stake represents 0.1% of the portfolio and ranks #242 among its holdings.

309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Cinctive Capital Management held 8,300 shares of Praxis Precision Medicines worth $2.78M as of Q2 2026.
Praxis Precision Medicines was a new Cinctive Capital Management position in Q2 2026.
Praxis Precision Medicines made up 0.1% of Cinctive Capital Management's portfolio in Q2 2026, its #242 holding.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.